While you can’t go back in time and invest in the alcohol industry at the end of Prohibition (and take part in the substantial stock gains that followed), the author of today’s article points out that “There is a similar situation developing around the globe currently as legal restrictions on cannabis production and consumption are being lifted” – a trend that “could result in a massive new industry with annual global revenues potentially hitting hundreds of billions if not over a trillion dollars.” What are the potential opportunities available to investors within “the cannabis theme”? CLICK HERE.
Low-priced stocks offer investors – especially more aggressive traders – the opportunity to not only make a decent profit in the event of even relatively small price moves, but also to buy more shares than they would be able to of large-cap stocks. Today’s article highlights five stocks trading under $10 that the authors believe “While more suited for aggressive accounts… could prove exciting additions to portfolios looking for solid alpha potential.” For these five stocks – including a company that “could be poised for big gains as liquefied natural gas (LNG) exporting continues to ramp higher”, CLICK HERE.
When it comes to low priced stocks, the author of today’s article points out that “These would be stocks that have little downside risk since they trade at low prices. These would also be the stocks that statistically have the highest probability of delivering a large gain in the next quarter.” In hunting for potential bargains, the author screened for low priced stocks that are beaten down and could be in the process of bottoming. For the specific screen employed and the three stocks that passed this screen, CLICK HERE.
“Reinvesting dividends can be the most significant factor in building wealth in the long run,” states the author of today’s article, who further notes that an investor could have increased their total return by more than 65% had they reinvested their dividends. As such, the author screened for promising dividend plays: “stocks priced under $20 with dividends that have increased over the past five years, show gains in earnings and strong financials.” For five stocks that passed this screen, CLICK HERE.
With only 10% of drug candidates that reach the clinical trial stage eventually making their way onto the market, knowing which small biotechs to bet on for big gains is no easy feat for investors. The author of today’s article suggests that one way investors can increase their odds of success is by identifying small biotechs that are getting the attention (and money) of big pharma companies. He proceeds to highlight one such company, which “has developed an innovative product that makes other drugs more effective” – attracting capital from the likes of Roche, Johnson & Johnson and more. To read about this company, the science behind its technology – and the opportunity for investors – CLICK HERE.
FANG stocks have been incredibly hot this year – and the exchange-traded fund highlighted in today’s article – which has demonstrated a penchant for strong fourth-quarter performances – could be an even bigger winner than usual as a result. The author notes that this ETF “has been one of the best performing U.S. ETFs during the last three months of the year since it debuted in mid 2006” – with an average fourth-quarter gain of 4.4%. To find out what this ETF is – and why it may be about to have its best showing in years – CLICK HERE.
Each of the 11 stocks highlighted in today’s article outperformed the market this summer – having returned more than 10% during the 3-month period in which the S&P 500 gained about 5%. More importantly, each of these stocks appears to still have room to run – and potentially continue to generate outsize returns – as they are all still trading below analysts’ fair value estimates. To find out what these 11 stocks are – and which three analysts are most confident in – CLICK HERE.
While it may seem like no retailer is safe from being snuffed out by Amazon, the authors of today’s article show how investors can still make big gains in this sector using the “Amazon Survivors” Index – a compilation of retailers that one research firm believes can survive the serial killer that is Amazon. What is the (surprising) best-performing stock in this index right now – and how can investors use the index’s inclusions (as well as its exclusions) to generate big gains? CLICK HERE.